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ABSTRACT
A nationwide laboratory-based surveillance study of invasive group A streptococcal (GAS) infections
was conducted in The Netherlands from May 1994 until December 2003 (average population during this
period was 15 729 704). Microbiologically invasive isolates were obtained from 1504 patients, with most
(70%) isolates cultured from blood. There was a clear seasonal pattern in invasive streptococcal
infections, with an estimated annual incidence that peaked in 1996 (4.0 cases ⁄ 100 000 individuals ⁄year)
and was at its lowest in 1999 (2.0 cases ⁄ 100 000 individuals ⁄ year). Twenty-eight different M-types were
identiﬁed, of which the most frequent were M1 (339 ⁄ 1504, 23%), M3 (187 ⁄ 1504, 12%), M89 (174 ⁄ 1504,
12%), M28 (164 ⁄ 1504, 11%), M12 (109 ⁄ 1504, 7%) and M6 (55 ⁄ 1504, 4%). There was a high degree of
variation in the relative annual contributions of the predominant M-types, but variations in M1 and M3
combined correlated with overall changes in the annual incidence. The contribution of the patient group
aged ‡ 56 years to all cases of invasive GAS disease increased during the study period, whereas that of
the group aged 0–20 years decreased. A peak in the incidence of invasive GAS disease among the
patient group aged 30–34 years did not vary during the study period, indicating that the high incidence
of invasive GAS disease in this age group was age-speciﬁc rather than cohort-related.
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lance, The Netherlands
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INTRODUCTION
Group A streptococci continue to represent a
major cause of infectious disease-linked morbid-
ity and mortality worldwide [1]. Although most
group A streptococcal (GAS) infections have a
mild clinical course, a certain proportion progress
to severe invasive disease, which can be compli-
cated by the development of streptococcal toxic
shock-like syndrome (TSS) [2,3]. A remarkable
feature of invasive GAS disease is its epidemiol-
ogy. After more than half a century of decreasing
morbidity and mortality, a resurgence and per-
sistence of severe invasive GAS infections has
been noted since the mid-1980s [1–6]. The cause
for this resurgence of streptococcal infections
remains enigmatic, and many hypotheses have
emerged, focusing either on impaired host
defences or an increase in the virulence of the
bacterium itself [7–9].
Previous studies have shown that immunity to
proteins and toxins that attach to the cell wall may
play a role in protection against severe invasive
disease [10]. The lack of protective anti-toxin
antibodies is known to be age-dependent [11].
Furthermore, a number of laboratory-based stud-
ies have suggested that the recent appearance of
serotypeswith increased virulencemayprovide an
explanation for the observed changes in GAS
epidemiology [2,12–17]. Increased intrinsic viru-
lence of someGAS types, particularly typesM1and
M3, has been reported [16,18–23]. These M-types
frequently produce streptococcal pyrogenic exo-
toxins, which have the capacity to non-speciﬁcally
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activate a large subset of T-cells, resulting in a
massive release of cytokines [24]. This mechanism
has been implicated in the pathogenesis of severe
complications such as TSS [25].
Only a few population-based prospective epi-
demiological studies [4,16,18,20,26–28] have
addressed the long-term dynamics of invasive
GAS disease and the contribution of ‘virulent’
M-types over time. The present study analysed
data obtained prospectively from a laboratory-
based nationwide surveillance system for inva-
sive GAS infections that has been ongoing for a
period of 10 years in The Netherlands. Changes in
the incidence and the relative contributions of
different M-types are addressed, as well as the
temporal dynamics of the population affected by
invasive GAS disease.
MATERIALS AND METHODS
Surveillance
A nationwide laboratory-based surveillance system for inva-
sive GAS infections in The Netherlands was formally organ-
ised with all regional public health laboratories (RPHLs) from
May 1994. There are 16 RPHLs in The Netherlands, covering
50% of the population. Financial support was provided to
RPHLs to enable submission of every GAS isolate from a
normally sterile body site, together with accompanying data
on the source of the isolate and the age, sex and place of
residence of the patient. Weekly reports on the number (or
absence) of GAS isolates obtained from normally sterile sites
were also submitted. This active surveillance system for
invasive GAS disease in The Netherlands (average population
during the study period was 15 729 704) remained in place
until December 2003.
Invasive GAS disease includes deﬁnite and probable cases
[29]. Deﬁnite cases were deﬁned as the isolation of GAS from a
normally sterile site in conjunction with clinical symptoms of
invasive bacterial disease. GAS isolation from a normally non-
sterile site in clinical association with invasive bacterial disease
was considered to be probable invasive GAS disease, but was
not included in this analysis. The study design of only
counting GAS isolates cultured from a normally sterile site
results in an underestimation of the incidence of invasive GAS
disease. The degree of underestimation was estimated using
data from a nationwide surveillance of invasive GAS disease,
which included clinical evaluation, that was conducted in The
Netherlands in the early 1990s [30]. In this previous study,
34% of patients with clinically invasive GAS disease had GAS
isolated from a non-sterile, unknown or indeterminate site.
These probable cases of invasive GAS disease represented the
limited sensitivity of the ‘microbiologically invasive’ criterion,
which had a speciﬁcity of 100%, but a sensitivity of only 66%
[30]. The previous study received 50% of isolates from RPHLs,
in accordance with the estimated coverage of the Dutch
population by RPHLs in the present study. Therefore, calcu-
lation of the incidence of invasive GAS disease in The
Netherlands from the present sentinel laboratory surveillance
included a correction for the limited sensitivity (· 100 ⁄ 66), as
well as a correction for the incomplete coverage of the
population by RPHLs (· 100 ⁄ 50).
Deﬁnition of invasiveness
Invasiveness was deﬁned solely on microbiological criteria,
i.e., the source of the isolate. GAS isolates obtained from blood,
cerebrospinal, pleural, peritoneal or joint ﬂuid, and aspirates
or biopsy materials from deep, normally sterile tissues (e.g.,
lung, kidney, bone marrow, uterus) were included. National
coverage of the RPHLs over the study period was constant,
and it was assumed that the sensitivity of the microbiological
deﬁnition of invasiveness (based on the period 1992–1996,
when all cases were also evaluated clinically) was constant
throughout the study period.
Identiﬁcation and typing
Isolates sent to the National Institute of Public Health (RIVM)
were conﬁrmed as GAS following bacitracin susceptibility and
latex agglutination tests (Streptex; Wellcome, Dartford, UK).
All GAS isolates were subjected to M-genotyping [31], thereby
allowing a direct comparison with the internationally applied
M-serotyping system.
Statistical analysis
Differences in group proportions were assessed by the chi-
square or Fisher’s exact test, with p values < 0.05 considered
signiﬁcant.
RESULTS
Incidence
From May 1994 to December 2003, the RIVM
received microbiologically invasive isolates of
GAS from 1504 patients. Most invasive isolates
were from blood (1047 ⁄ 1504, 70%), with other
isolation sites or specimens including aspirates
of abscesses, intra-operative or post-mortem swabs
or tissue (118 ⁄ 1504, 8%), respiratory tract
(114 ⁄ 1504, 8%), synovial ﬂuid (69 ⁄ 1504, 5%),
perineal or genital tract (47 ⁄ 1504, 3%), cerebrospi-
nal ﬂuid (38 ⁄ 1504, 2%) and others (71 ⁄ 1504, 5%).
The absolute number of cases obtained ⁄month
during the period May 1994 to January 2004 is
shown in Fig. 1. There was a clear seasonal pattern
in invasive streptococcal infections, with a low
incidence at the end of each year, and with most
cases occurring in late winter and spring. The
estimated annual incidence from 1995 until 2003 is
shown in Fig. 2. The estimated incidence was
highest in 1996 (4.0 ⁄ 100 000 individuals ⁄ year),
and also relatively high in 2002 (3.1 ⁄ 100 000 indi-
viduals ⁄year), with a lowest estimated incidence
of 2.0 ⁄ 100 000 individuals ⁄ year in 1999.
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M-types
Twenty-eight different M-types were identiﬁed, of
which themost frequent wereM1 (339 ⁄ 1504, 23%),
M3 (187 ⁄ 1504, 12%), M89 (174 ⁄ 1504, 12%), M28
(164 ⁄ 1504, 11%), M12 (109 ⁄ 1504, 7%) and M6
(55 ⁄ 1504, 4%). Other M-types constituted 19%
(292 ⁄ 1504) of the isolates, but although all isolates
yielded an emm amplicon, a further 184 ⁄ 1504
(12%) did not hybridise with one of the M-type-
speciﬁc probes (i.e., they were M-non-typeable).
There was considerable variation in the relative
prevalence of the predominantM-types during the
study period. Thus, the proportion of M1 invasive
isolates varied (Fig. 2) from 11% to 12% in 1995
(23 ⁄ 197) and 1999 (11 ⁄ 100) to 40% in 2001 (62 ⁄ 154).
M3 isolates were rare in 2000, but comprised
almost 20% of all invasive isolates in 1995 (35 ⁄ 197)
and 2002 (27 ⁄ 160). The relative proportions of M1
and M3 combined correlated with the overall
annual incidence (Fig. 2). Among the predominant
M-types, M1, M3 and M6 showed the highest
ﬂuctuations in their relative annual contributions
(Fig. 2).
Age ⁄ sex distribution of invasive GAS isolates
The date of birth was known for all cases in the
present study. On the basis of a previous report
[30] that described three age groups in relation to
the risk of contracting invasive GAS infections,
Fig. 3 shows the relative proportions of the age
groups 0–20, 21–55 or ‡ 56 years. The group aged
‡ 56 years constituted 39% of all invasive cases
in 1995 (76 ⁄ 197), increasing to > 50% in 2002
(82 ⁄ 160) and 2003 (80 ⁄ 157). The relative contribu-
tion of the youngest group (aged < 20 years)
decreased from 19% (38 ⁄ 197) in 1995 to 8%
(13 ⁄ 157) in 2003. Fig. 4 indicates that the peak in
incidence for patients aged 30–34 years did not
vary signiﬁcantly during the 10-year surveillance
period. This was the case for both men and
women (results not shown).
DISCUSSION
The data from this study, obtained during a
decade of nationwide laboratory-based surveil-
lance of invasive GAS disease, indicated that the
incidence of disease was highest in 1995 and
1996 (4.0 ⁄ 100 000 individuals ⁄year), with a sim-
ilar level almost being reached again in 2002.
The lowest incidence was in 1999 (2.0 ⁄ 100 000
individuals ⁄ year). Sharkawy et al. [26] reported
a nearly two-fold increase in the incidence of
invasive GAS infections during a 5-year surveil-
lance period in Ontario, Canada. The highest
incidence in 1995 was similar to that reported
from the USA and Israel [27,32], while the
lowest incidence in the present study was
similar to that reported from Ontario [18] and
Sweden [13].
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Fig. 1. Monthly distribution (ob-
served absolute number of cases ⁄
month) of invasive group A
streptococcal disease in The
Netherlands (May 1994 to December
2003).
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Fig. 2. Annual incidence (cases ⁄
100 000 individuals ⁄ year) of inva-
sive group A streptococcal disease
and the proportion of M1, M3, M89,
M28, M12, M6, non-typeable and
other M-types in The Netherlands
(1995–2003).
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For incidence calculations, it was necessary to
make corrections for the national coverage of
participating RPHLs, and for the fact that only
isolates obtained from normally sterile sites were
included. No signiﬁcant changes occurred in the
national coverage of RPHLs during the study
period, and a previous study from 1992 to 1996
found that a constant proportion of 66% of all
cases of invasive GAS disease were associated
with isolation of the bacterium from a sterile site
[30]. This sensitivity level was extrapolated for the
present study, but it is not absolutely certain that
it has remained constant over time.
Some studies, either historical [33] or hospital-
based [34], have described cyclical peaks in the
incidence of invasive GAS disease every
3–4 years. This was not observed in the present
study, but in accordance with other reports
[13,18,20,21], a clear seasonal pattern was noticed,
with a sharp increase in incidence in late winter
and a low incidence in summer, during the
10 years of the study.
It has been reported previously that changes in
the incidence of infections associated with M1
isolates is the main explanation for changes in the
overall incidence of invasive GAS disease [13,35].
The present study found that the contribution of
M1 isolates, and of M1 and M3 isolates combined,
correlated with the overall annual incidence.
These two M-types are associated particularly
with TSS and fatality [36]. Therefore, cases of GAS
disease may have a more severe course during
periods with a high overall incidence of invasive
GAS disease.
The overall prevalence of M1 isolates was 23%.
Other M-types identiﬁed frequently were M3
(12%), M89 (12%), M28 (11%), M12 (7%) and
M6 (4%). In total, 12% of all isolates were M-non-
typeable, which is consistent with other reports
[37,38]. The high prevalence of M1 isolates was
expected following the results of other studies.
However, in a study conducted in the 1980s by
the UK Central Public Health Laboratory, the
prevalence of M1 isolates was much lower
(10.4%) [38], although almost half of all isolates
originated from throat swabs. Davies et al. [18]
reported prevalences of 24% for M1, 7.4% for
M12, 6.5% for M4, 6.2% for M28, and 5.8% for
M3, while O’Brien et al. [20] found that these
M-types accounted for 20.8%, 7.6%, 4.1%, 9.2%
and 7.1%, respectively, of invasive isolates. Tyrell
et al. [37] reported that M1 isolates accounted for
28.2% of all blood culture isolates, and argued
that this much higher proportion, compared to
the UK, might be caused either by geographical
reasons or by the fact that the UK study included
a large number of non-invasive isolates. In a
previous study in The Netherlands [19], it was
found that M1 and M3 isolates were over-repre-
sented among isolates associated with TSS and
mortality, supporting the hypothesis that these
serotypes have enhanced virulence [19]. Further-
more, a separate nationwide study conducted in
The Netherlands in 1994–1995 [39], investigating
pharyngeal carriage of GAS, showed a much
lower proportion (4.5%) of M1 isolates, thereby
providing evidence for an association of this
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serotype with invasiveness. Therefore, the inclu-
sion of non-invasive isolates in some studies
might provide an explanation for a lower inci-
dence of M1 isolates. However, the dynamics of
M1 isolates over time should be emphasised. In
the present study, involving a clearly deﬁned
geographical region, the yearly proportion of M1
isolates among all invasive isolates varied from
10% to 40%, with no evidence for the occurrence
of local outbreaks. This hampers any comparison
of the proportions of M1 isolates in different
geographical regions over different time periods.
The proportion of any particular M-type among
all invasive isolates reﬂects the prevalence of that
serotype in the community, its invasiveness and
the M-speciﬁc immunity in the population [20].
However, contemporaneous data regarding all
non-invasive isolates circulating in the commu-
nity is lacking. Therefore, it is not clear whether
the observed ﬂuctuations in the incidence of
invasive infections with M1 and M3 isolates
reﬂect the dynamics in the community or relative
alterations in invasiveness or population immu-
nity. Of the predominant M-types, M1, M3 and
M6 isolates showed the most conspicuous ﬂuctu-
ations. Notably, these are the M-types that were
found previously to be highly clonal in nature
[36].
A high incidence of invasive infections in the
elderly and youngest age groups is well-recog-
nised [4,18,20,21,26,27,35,37,40]. In the present
study, both men and women in the middle-aged
category also had an increased incidence of
invasive GAS disease. Whether this is associated
with (selective) decreased immunity in the mid-
dle-aged group [41] or re-exposure through
household contacts is unclear. However, it does
not appear to be a cohort phenomenon, as the
peak in the middle-aged group did not shift
correspondingly during a decade of surveillance.
Previous studies have shown that immunity to
proteins and toxins that attach to the cell wall may
play a role in protection against severe invasive
disease [10]. Furthermore, a lack of protective
anti-toxin antibodies has been found to be age-
dependent [11,29]. The present study provides
epidemiological support that this is speciﬁc for an
age group rather than a cohort. However, there
was a change in the relative contributions of the
different age groups to all invasive GAS infec-
tions, in that the group aged 0–20 years contribu-
ted progressively less, while the group aged
‡ 56 years gradually contributed more. This
change was not paralleled by any signiﬁcant
alterations in the population age distribution
during the decade of the study.
In summary, the epidemiology of invasive GAS
disease and the contribution of individual
M-types evolve over time. Considering the over-
all dynamics of the various M-types, and the
possibility of the appearance of new serotypes
[2,12–17], continued monitoring of the distribu-
tion of different serotypes is necessary. New
M-types, or virulent clones within a serotype,
might appear and, with little speciﬁc immunity in
the population, gain predominance. Population-
based surveillance provides data for monitoring
incidence trends and identifying the importance
of particular virulent strains, thus providing a
rational basis for disease control measures and
future vaccine development.
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